HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

L 644711 (B-3(+))

RN given refers to (R)-isomer; structure given in first source; HCO3(-)/Cl(-) antiporter antagonist

Also Known As:

B-3(+); ((5,6-dichloro-2,3,9,9a-tetrahydro-3-oxo-9a-propyl-1H-fluoren-7-yl)oxy)acetic acid; ((5,6-dichloro-9a-n-propyl-2,3,9,9a-tetrahydro-3-oxo-1H-fluren-7-yl)oxy)acetic acid; DPOFA; L 644711, (S)-isomer; L-644,711

Networked: 275 relevant articles (8 outcomes, 17 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Society of Obstetricians and Gynaecologists of Canada: 3 articles (03/2015 - 06/2009)
2.	Breiteneder, H: 3 articles (08/2003 - 04/2000)
3.	Scheiner, O: 3 articles (08/2003 - 04/2000)
4.	Wagner, B: 3 articles (08/2003 - 04/2000)
5.	Kinghorn, A Douglas: 2 articles (10/2015 - 06/2007)
6.	Case, Allison: 2 articles (03/2015 - 11/2011)
7.	Liu, Kimberly: 2 articles (03/2015 - 11/2011)
8.	Reproductive Endocrinology and Infertility Committee: 2 articles (03/2015 - 11/2011)
9.	Allaire, Catherine: 2 articles (02/2015 - 01/2002)
10.	Menticoglou, Savas: 2 articles (12/2013 - 06/2009)

Related Diseases

1.	Neoplasms (Cancer) 05/01/1995 - "His postoperative pathological study was revealed intramural bronchial cancer at B 3 orifice without node involvement. " 05/01/2012 - "Based on histologic follow-up, the risk of neoplasm (including benign and malignant neoplasm) was B 14%, AUS 44%, FN 67%, SM 77%, and M 100% and the risk of malignancy was B 3%, AUS 6%, FN 22%, SM 56%, and M 100%. " 06/01/2008 - "The cancer specific mortality from group A is 24 (71%) and in group B 3 (7%) (p = 0.000). " 10/01/2007 - "All patients had T1-2 tumors with < or b=3 axillary nodes positive, nonlobular histology, negative surgical margins, and no evidence of extracapsular lymph node extension. " 05/01/2007 - "Furthermore, cancer EST variations were not random, but were determined by the composition of the substituted base (b0) as well as that of the bases located upstream (up to b - 4) and downstream (up to b + 3) of the substitution event. "
2.	Myocarditis (Carditis) 08/01/2010 - "To observe the effect of Chinese herbal compound for supplementing qi and activating blood circulation (CHC) on the gap junctional intercellular communication (GJIC) function of myocardial cells in patients with Coxsackie virus B 3 (CVB3) viral myocarditis. " 08/01/1995 - "The data suggest (a) that a cumulative loss of cardiac myofibers, induced either by the virus and/or by immune reactions to the heart, is likely to lead to a late depression of cardiac function, and (b) that there is a weak and only temporary structure-function relationship in the heart in coxsackievirus B 3 myocarditis. " 08/01/1995 - "Left ventricular hemodynamic parameters in the course of acute experimental coxsackievirus B 3 myocarditis." 07/01/1981 - "A small amount of coxsackie B 3 virus frequently caused mild myocarditis without obvious residual pathologic changes of the heart, while a large amount of the same virus always caused acute and severe myocarditis. " 12/01/1972 - "Murine myocarditis due to coxsackie B 3 virus: blood amino acid, virologic, and histopathologic correlates."
3.	Spinal Dysraphism (Spina Bifida) 04/15/2000 - "Characterization of T cell responses to Hev b 3, an allergen associated with latex allergy in spina bifida patients." 11/01/1999 - "Cloning, expression, and characterization of recombinant Hev b 3, a Hevea brasiliensis protein associated with latex allergy in patients with spina bifida." 01/01/2001 - "Development of recombinant Hev b 3, a major NRL allergen relevant to children with spina bifida, enhances the likelihood for improved diagnostic reagents. " 05/01/2002 - "In addition, Hev b 3 and Hev b 1, the two major allergens for children with spina bifida, are also commonly found. " 02/01/1999 - "Cloning and molecular characterization of Hev b 3, a spina-bifida-associated allergen from Hevea brasiliensis latex."
4.	Ischemia 12/01/2010 - "Outcomes among different ischemia time groups were evaluated: group A, less than 3 hours; group B, 3 to 4 hours; group C, 4 to 5 hours; and group D, 5 to 7 hours. " 03/01/1990 - "The eyes were then classified in four categories according to the extent and location of capillary nonperfusion responsible for the NVE, namely 1) generalized ischemia (Type A); 2) extensive midperipheral ischemia (Type B); 3) moderate midperipheral ischemia (Type C); and 4) peripheral ischemia (Type D). " 08/01/1986 - "Animals given dexamethasone were divided into three groups and the drug was administered at a constant dosage of 2 mg/kg: (a) 2 days, 1 day, and 3 h intraperitoneally before (chronic pretreatment), (b) 3 h intraperitoneally before (acute pretreatment), and (c) 5 min intravenously and 6 h and 1 day intraperitoneally after (chronic posttreatment) induction of ischemia. " 04/01/1998 - "In the experimental protocol B, 3 min of cardioplegia without TH and 34 min of ischemia (37 degrees C) were followed by a 10 min Langendorff reperfusion with various concentrations of TH, then 10 min Langendroff reperfusion for washing out, and 20 min working reperfusion. " 11/01/2003 - "Previous studies have shown that administration of vitamin B(3) (B(3)) in animal models of ischemia significantly reduced the size of infarction and improved functional recovery. "
5.	Infarction 11/01/2003 - "Previous studies have shown that administration of vitamin B(3) (B(3)) in animal models of ischemia significantly reduced the size of infarction and improved functional recovery. "

Related Drugs and Biologics

1.	Niacinamide (Nicotinamide)
2.	Indicators and Reagents (Reagents)
3.	Ethiodized Oil (Ethiodol)
4.	Win 54954
5.	Latex
6.	Allergens
7.	Immunoglobulin E (IgE)
8.	Peptides
9.	Insulin (Novolin)
10.	Acetic Acid (Vinegar)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Hysterectomy
3.	Oral Administration
4.	Liver Transplantation
5.	Transplantation (Transplant Recipients)